A prescription-only intravenous Alzheimer’s treatment has launched in India at Rs 91,688 for a 350 mg vial. The monthly therapy can be given for up to 18 months, making the total cost potentially steep for many patients. The drug targets the underlying disease process linked to amyloid plaque buildup and neurofibrillary tangles in the brain.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
